Sept 8: At the end of July, Citius Pharmaceuticals received a Complete Response Letter from the FDA pertaining to its Biologics License Application for Lymphir, an engineered IL-2-diphtheria toxin fusion protein intended to treat relapsed or refractory cutaneous T-cell lymphoma
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC
Type 2 diabetes as a disease of ectopic fat
The Metabolic Imperative Metabolic health situates the biological environment in which conception unfolds
Phase Ib/II Randomized, Open-Label Study of Doxorubicin and Cyclophosphamide with or without Low-Dose, Short-Course Sunitinib in the Pre-operative Treatment of Breast Cancer
Rather than mimicking gut hormones to suppress appetite, it stimulates the pituitary gland to produce and release more natural growth hormone